← Leaderboards
Robert A Rissman
University Of California Irvine
$44,753,017
Attributed
$92,605,803
Total exposure
29
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $47M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$207,751,497 · 28
VA$0 · 2
By mechanism
U19$125,717,784 · 3
R01$65,760,426 · 9
RF1$8,360,799 · 4
P30$3,562,009 · 4
R56$2,789,836 · 3
R21$1,279,400 · 3
Top collaborators
- Sid E O'Bryant23 shared
- Arthur W Toga11 shared
- Leigh A Johnson10 shared
- Charles Karan5 shared
- Constantine G Lyketsos5 shared
- Victoria B Risbrough5 shared
- Pietro P Sanna5 shared
- Paul E. Sawchenko5 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseTau ProteinsImpaired CognitionClinical TrialsSamplingBiological MarkersPlasmaNerve DegenerationPathologyPharmaceutical PreparationsAmyloid Beta-ProteinNeuronsBaseCohortCognitiveBrainPreventParticipantExosomeBiobankAmyloidBloodEnrollment
Grant awards (90)
The Health & Aging Brain Study - Health Disparities (HABS-HD)$31,789,574
U19 · FY2025 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study$8,926,202
R01 · FY2025 · AG
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome$604,405
R01 · FY2025 · AG · contact PI
Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease$582,487
R01 · FY2025 · AG · contact PI
Biomarker Core$520,120
P30 · FY2025 · AG · contact PI
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies$485,466
R01 · FY2025 · AG · contact PI
The Health & Aging Brain Study - Health Disparities (HABS-HD)$27,991,499
U19 · FY2024 · AG
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome$623,408
R01 · FY2024 · AG · contact PI
Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease$594,041
R01 · FY2024 · AG · contact PI
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies$578,101
R01 · FY2024 · AG · contact PI
The Health & Aging Brain Study - Health Disparities (HABS-HD)$27,709,139
U19 · FY2023 · AG
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study$9,074,729
R01 · FY2023 · AG
Impact of TBI and Cognitive Decline on Alzheimer's Disease Brain-Derived Exosome Cargo$1,948,168
RF1 · FY2023 · AG · contact PI
Biomarker Core$318,080
P30 · FY2023 · AG · contact PI
Neuropathology Core$312,448
P30 · FY2023 · AG · contact PI
Core B - Biomarkers$239,635
P01 · FY2023 · AG · contact PI
Biomarker Core$232,219
P30 · FY2023 · AG · contact PI
The Health & Aging Brain Study - Health Disparities (HABS-HD)$27,655,482
U19 · FY2022 · AG
HABS-HD - Core D - Omics Core$9,180,539
U19 · FY2022 · AG · contact PI
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study$9,074,729
R01 · FY2022 · AG
Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease$354,521
RF1 · FY2022 · AG · contact PI
Neuropathology Core$292,152
P30 · FY2022 · AG · contact PI
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome$249,999
RF1 · FY2022 · AG · contact PI
Biomarker Core$218,207
P30 · FY2022 · AG · contact PI
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI$0
I01 · FY2022 · VA
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study$9,059,887
R01 · FY2021 · AG
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome$2,328,791
RF1 · FY2021 · AG · contact PI
Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies$1,751,085
RF1 · FY2021 · AG · contact PI
A Blood Test for Screening Into Alzheimer's Prevention Trials$560,088
R01 · FY2021 · AG
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$506,300
R01 · FY2021 · AG · contact PI
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$395,000
R01 · FY2021 · AG · contact PI
Neuropathology Core$328,573
P30 · FY2021 · AG · contact PI
Biomarker Core$246,615
P30 · FY2021 · AG · contact PI
Administrative Supplement: Improving AI/ML-Readiness of data generated from HALBE or other NIH-funded research$142,142
R01 · FY2021 · AG
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI$0
I01 · FY2021 · VA
Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study$9,147,291
R01 · FY2020 · AG
Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease$1,728,235
RF1 · FY2020 · AG · contact PI
Systems biology of HIV, methamphetamine and antiretrovirals interactions$866,634
R01 · FY2020 · DA
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,564
R01 · FY2020 · AG
A Blood Test for Screening Into Alzheimer's Prevention Trials$560,088
R01 · FY2020 · AG
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$506,300
R01 · FY2020 · AG · contact PI
Identifying Molecular Signatures associated with Alzheimer's Disease in the Retina$433,875
R21 · FY2020 · AG · contact PI
Neuropathology Core$311,459
P30 · FY2020 · AG · contact PI
Biomarker Core$234,911
P30 · FY2020 · AG · contact PI
Validation Studies of CRF Receptor 1 as a Target for AD$0
I01 · FY2020 · VA · contact PI
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI$0
I01 · FY2020 · VA
Systems biology of HIV, methamphetamine and antiretrovirals interactions$872,331
R01 · FY2019 · DA
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$813,603
R01 · FY2019 · AG
A Blood Test for Screening Into Alzheimer's Prevention Trials$560,088
R01 · FY2019 · AG
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$506,300
R01 · FY2019 · AG · contact PI
A Blood Test for Screening into Alzheimer's Prevention Trials$364,794
R01 · FY2019 · AG
Neuropathology Core$311,295
P30 · FY2019 · AG · contact PI
Biomarker Core$235,930
P30 · FY2019 · AG · contact PI
BIOMARKER CORE$223,751
U19 · FY2019 · AG · contact PI
Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI$0
I01 · FY2019 · VA
Validation Studies of CRF Receptor 1 as a Target for AD$0
I01 · FY2019 · VA · contact PI
Amyloid Burden among Mexican Americans$1,113,198
R56 · FY2018 · AG
Systems biology of HIV, methamphetamine and antiretrovirals interactions$878,554
R01 · FY2018 · DA
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,543
R01 · FY2018 · AG
A Blood Test for Screening Into Alzheimer's Prevention Trials$567,388
R01 · FY2018 · AG
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$506,300
R01 · FY2018 · AG · contact PI
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$392,500
R01 · FY2018 · AG · contact PI
Proinflammatory Endophenotype to predict NSAID treatment response Alzheimer's trials$143,225
R01 · FY2018 · AG
Validation Studies of CRF Receptor 1 as a Target for AD$0
I01 · FY2018 · VA · contact PI
Systems biology of HIV, methamphetamine and antiretrovirals interactions$884,928
R01 · FY2017 · DA
Proteomic characterization of exosomes from AD patients$844,015
R56 · FY2017 · AG
Biogenesis of Exosomes, Secretion, and Trafficking in Alzheimer's Disease$832,623
R56 · FY2017 · AG · contact PI
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$681,438
R01 · FY2017 · AG
A Blood Test for Screening Into Alzheimer's Prevention Trials$578,888
R01 · FY2017 · AG
a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease$506,300
R01 · FY2017 · AG · contact PI
BIOMARKER CORE$221,844
U19 · FY2017 · AG · contact PI
Pathogenicity of neuronally-derived tau in exosomes$193,750
R21 · FY2017 · AG · contact PI
Validation Studies of CRF Receptor 1 as a Target for AD$0
I01 · FY2017 · VA · contact PI
Systems biology of HIV, methamphetamine and antiretrovirals interactions$937,707
R01 · FY2016 · DA
A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials$742,047
R01 · FY2016 · AG
Pathogenicity of neuronally-derived tau in exosomes$232,500
R21 · FY2016 · AG · contact PI
BIOMARKER CORE$220,796
U19 · FY2016 · AG · contact PI
Validation Studies of CRF Receptor 1 as a Target for AD$0
I01 · FY2016 · VA · contact PI
a-synuclein clearance strategies for the treatment of Lewy body disease$275,621
R01 · FY2015 · AG · contact PI
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism$225,525
R21 · FY2015 · AG
BIOMARKER CORE$225,185
U19 · FY2015 · AG · contact PI
BIOMARKER CORE$216,991
U19 · FY2014 · AG · contact PI
Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism$193,750
R21 · FY2014 · AG
BIOMARKER CORE$282,984
U19 · FY2013 · AG · contact PI
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis$363,748
R01 · FY2012 · AG
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis$363,748
R01 · FY2011 · AG
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis$378,431
R01 · FY2010 · AG
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis$400,943
R01 · FY2009 · AG
Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis$391,139
R01 · FY2008 · AG
Role of Intracellular ABeta in Tau Pathology$41,608
F32 · FY2003 · AG